- Home
- ASG vs PRQR Comparison
ASG vs PRQR Comparison
Compare ASG & PRQR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ASG | PRQR |
|---|---|---|
| Founded | 1986 | 2012 |
| Country | United States | Netherlands |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 334.6M | 250.7M |
| IPO Year | N/A | 2014 |
Fundamental Metrics
Financial Performance| Metric | ASG | PRQR |
|---|---|---|
| Price | $5.34 | $1.96 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $8.14 |
| AVG Volume (30 Days) | 324.3K | ★ 658.1K |
| Earning Date | 01-01-0001 | 11-06-2025 |
| Dividend Yield | ★ 8.09% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $18,859,556.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $19.56 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $4.47 | $1.07 |
| 52 Week High | $5.71 | $3.10 |
Technical Indicators
Market Signals| Indicator | ASG | PRQR |
|---|---|---|
| Relative Strength Index (RSI) | 51.12 | 39.95 |
| Support Level | $5.19 | $2.03 |
| Resistance Level | $5.42 | $2.31 |
| Average True Range (ATR) | 0.06 | 0.17 |
| MACD | 0.01 | -0.02 |
| Stochastic Oscillator | 72.00 | 3.48 |
Price Performance
Historical ComparisonAbout ASG Liberty All-Star Growth Fund Inc.
Liberty All Star Growth Fund Inc is the United States based diversified, closed-end management investment company. Its investment objective is to seek long-term capital appreciation through investment in a diversified portfolio of equity securities. The company portfolio of investments consists of different industries such as consumer discretionary, consumer staples, healthcare, industrial, information technology and others.
About PRQR ProQR Therapeutics N.V.
ProQR Therapeutics NV is a biopharmaceutical company. It discovers and develops RNA therapeutics for patients with severe genetic rare diseases such as cystic fibrosis, Leber congenital amaurosis type 10, and dystrophic epidermolysis bullosa. The only reportable segment of the company is the discovery and development of different, RNA-based therapeutics.